CJA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Résumé de cet Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a scholarly reply
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ickx, B. E.
Right arrow Articles by Steib, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ickx, B. E.
Right arrow Articles by Steib, A.
Canadian Journal of Anesthesia 53:S113-S122 (2006)
© Canadian Anesthesiologists' Society, 2006

Managing patients on antithrombotic therapy and their complications

Perioperative management of patients receiving vitamin K antagonists

[Prise en charge périopératoire des patients traités aux antagonistes de la vitamine K]

Brigitte E. Ickx, MD* and Annick Steib, MD{dagger}

* From the Departments of Anesthesiology, Hôpital Erasme, Bruxelles, Belgium; and
{dagger} Hôpital Civil, Strasbourg, France.

Address correspondence to: Dr. Brigitte E. Ickx, Department of Anesthesiology, Hôpital Erasme, 808, Route de Lennik, 1070 Bruxelles, Belgium. Phone: + 322 555 4658; Fax: + 322 555 4363; E-mail: brigitte.ickx{at}ulb.ac.be

Purpose: As the number of patients taking vitamin K antagonists (VKA) is growing, the clinician is increasingly faced with having to make decisions regarding anticoagulation therapy before, during and immediately after surgery. In this article we review the indications for VKA and assess their use in the perioperative period based on available pharmacological and clinical data.

Source: An on-line computerized search of Medline was conducted limited to English and French language articles. The bibliographies of relevant articles and additional material from other published sources were retrieved and reviewed.

Principal findings: Assessment of patients taking VKA who need surgery must include three factors: 1) the indication for anticoagulation, which determines the thromboembolic risk; 2) the pharmacokinetics of VKA, which determine the moment at which treatment should be discontinued; and 3) the type of surgery, which determines the hemorrhagic risk. Some patients will need to stop VKA treatment and start a substitution or "bridging" anticoagulant therapy, such as unfractionated heparin or low molecular weight heparin, prior to and after surgery. In patients requiring emergency surgery, prothrombin complex concentrate can be used to improve coagulation and is preferable to, although more expensive than fresh frozen plasma.

Conclusions: For the perioperative setting, further studies are required to determine the optimal substitution ("bridging") regimen and the clinical circumstances that necessitate substitution therapy.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the Canadian Anesthesiologists' Society.